Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 8-K, filing, corporate-update
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K on Nov 17, 2025. No major news, just a standard update.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on November 17, 2025, reporting on other events and financial statements. The filing does not disclose specific new material events or financial figures but serves as a routine update.
Why It Matters
This 8-K filing from Tonix Pharmaceuticals is a routine update that may contain important disclosures about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K and does not appear to contain any immediately alarming or significant new information.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- November 17, 2025 (date) — Date of report
- 26 Main Street, Chatham, New Jersey, 07928 (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Tonix Pharmaceuticals Holding Corp.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of November 17, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is November 17, 2025.
What is the state of incorporation for Tonix Pharmaceuticals Holding Corp.?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.
What is the business address of Tonix Pharmaceuticals Holding Corp.?
The business address of Tonix Pharmaceuticals Holding Corp. is 26 Main Street, Suite 101, Chatham, New Jersey, 07928.
What was the former company name of Tonix Pharmaceuticals Holding Corp.?
The former company name of Tonix Pharmaceuticals Holding Corp. was TAMANDARE EXPLORATIONS INC.
Filing Stats: 786 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2025-11-17 07:05:34
Filing Documents
- tnxp-8k_111725.htm (8-K) — 27KB
- ex99-01.htm (EX-99.01) — 31KB
- tonix.jpg (GRAPHIC) — 4KB
- 0001999371-25-017964.txt ( ) — 235KB
- tnxp-20251117.xsd (EX-101.SCH) — 3KB
- tnxp-20251117_lab.xml (EX-101.LAB) — 33KB
- tnxp-20251117_pre.xml (EX-101.PRE) — 22KB
- tnxp-8k_111725_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On November 17, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced that TONMYA TM (cyclobenzaprine HCl sublingual tablets) is commercially available at pharmacies by prescription in the United States. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On November 17, 2025, the Company announced that TONMYA TM is commercially available at pharmacies by prescription in the United States.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, dated November 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: November 17, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer